# US 2021/0239711 A1 · Biomarkers for early diagnosis of chronic hip displasia and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0239711 A1
- Document ID: US20210239711A1
- Status: Published application
- Kind: A1
- Application number: 17/168,871
- Filed: 2021-02-05
- Published: 2021-08-05
- Earliest claimed: 2020-02-05
- Assignees: The Curators of the University of Missouri
- Applicants: The Curators of the University of Missouri
- Inventors: James L. Cook; Aaron M. Stoker; Chantelle C. Bozynski; Keiichi Kuroki; Cristi R. Cook; Emily Leary
- Web page: https://patentgrep.com/patent/US20210239711A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/10: Musculoskeletal or connective tissue disorders
- G01N 2800/38: Pediatrics
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for predicting canine hip dysplasia (CHD) in an immature canine subject are provided. The methods include the use of concentration profiles of a plurality of polypeptides, including C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP. Also provided are CHD biomarker profiles for predicting or diagnosing CHD in immature or young canines before CHD develops. Diagnostic reagents and kits for the same are also provided.

## Claims

### Claim 1

A method for diagnosing canine hip dysplasia (CHD) in an immature canine subject, the method comprising:
obtaining a biological sample from an immature canine subject;
measuring in the biological sample from the immature canine subject a concentration of at least two polypeptides selected from the group consisting of: C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP;
generating a sample polypeptide concentration profile based on the concentration of the at least two polypeptides in the biological sample, wherein an elevated or decreased concentration of the at least two polypeptides in the biological sample, as compared to a control, provides a sample polypeptide concentration profile indicative of CHD, wherein a concentration of the at least two polypeptides in the biological sample that is not elevated or decreased, as compared to a control, provides a sample polypeptide concentration profile not indicative of CHD; and using the generated sample polypeptide concentration profile to diagnose CHD in the immature canine subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immature canine subject is a canine that has not reached skeletal maturity or is less than about one year of age.

### Claim 3 (depends on 1)

The method of claim 1, wherein the immature canine subject is a canine that is less than about six months of age.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological sample comprises any one of urine, whole blood, blood plasma, synovial fluid and serum.

### Claim 5 (depends on 1)

The method of claim 1, wherein the biological sample comprises urine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the concentration of at least three polypeptides selected from the group consisting of C2C, CTX-I, CTX-II, RANKL, PIICP, COMP and PINP is measured, and wherein the sample polypeptide concentration profile is based on the concentration of the at least three polypeptides in the biological sample.

### Claim 7 (depends on 6)

The method of claim 6, wherein an elevated or decreased concentration of at least two of the three polypeptides in the biological sample, as compared to a control, provides a sample polypeptide concentration profile indicative of CHD.

### Claim 8 (depends on 6)

The method of claim 6, wherein an elevated or decreased concentration of the three polypeptides in the biological sample, as compared to a control, provides a sample polypeptide concentration profile indicative of CHD.

### Claim 9 (depends on 1)

The method of claim 1, wherein the concentration of at least four polypeptides selected from the group consisting of C2C, CTX-I, CTX-II, RANKL, PIICP, COMP and PINP is measured, and wherein the sample polypeptide concentration profile is based on the concentration of the at least four polypeptides in the biological sample.

### Claim 10 (depends on 9)

The method of claim 9, wherein an elevated or decreased concentration of at least three of the four polypeptides in the biological sample, as compared to a control, provides a sample polypeptide concentration profile indicative of CHD.

### Claim 11 (depends on 9)

The method of claim 9, wherein an elevated or decreased concentration of the four polypeptides in the biological sample, as compared to a control, provides a sample polypeptide concentration profile indicative of CHD.

### Claim 12 (depends on 1)

The method of claim 1, wherein the concentration of each of C2C, CTX-I, CTX-II and RANKL is measured in a urine sample from the immature canine subject, and wherein the sample polypeptide concentration profile is based on the concentration of each of C2C, CTX-I, CTX-II and RANKL in the urine sample.

### Claim 13 (depends on 1)

The method of claim 1, wherein the concentration of each of C2C, COMP, PIICP, CTX-II and RANKL is measured in a serum sample from the immature canine subject, and wherein the sample polypeptide concentration profile is based on the concentration of each of C2C, COMP, PIICP, CTX-II and RANKL in the serum sample.

### Claim 14 (depends on 1)

The method of claim 1, wherein the concentration of the at least two polypeptides in the biological sample is measured using a method selected from the group consisting of: LUMINEX, ELISA, immunoassay, mass spectrometry, high performance liquid chromatography, two-dimensional electrophoresis, in situ hybridization, SAGE, Western blotting, protein microarray, and antibody microarray.

### Claim 15

A canine hip dysplasia (CHD) biomarker profile comprising polypeptide concentration levels for two or more polypeptides selected from the group consisting of: C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP, and fragments (e.g. portion of the full protein structure) of any thereof, and any combination thereof, obtained from a biological sample from at least one immature canine subject susceptible to having and/or developing CHD.

### Claim 16 (depends on 15)

The CHD biomarker profile of claim 15, further comprising polypeptide concentration levels for at least one biological sample obtained from at least one healthy canine subject and/or a canine subject not susceptible to developing CHD.

### Claim 17 (depends on 16)

The CHD biomarker profile of claim 16, wherein the biological samples from the immature canine subject susceptible to having and/or developing CHD and the healthy subject and/or the subject not susceptible to developing CHD both comprise a sample selected from the group consisting of urine, whole blood, blood plasma and serum.

### Claim 18 (depends on 17)

The CHD biomarker profile of claim 17, wherein the biological samples are urine sample.

### Claim 19 (depends on 15)

The CHD biomarker profile of claim 15, comprising polypeptide concentration levels for three or more polypeptides selected from the group consisting of C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP.

### Claim 20 (depends on 15)

The CHD biomarker profile of claim 15, comprising polypeptide concentration levels for four or more polypeptides selected from the group consisting of C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP.

### Claim 21 (depends on 15)

The CHD biomarker profile of claim 15, comprising polypeptide concentration levels of each of C2C, CTX-I, CTX-II and RANKL, wherein the sample is a urine sample.

### Claim 22 (depends on 15)

The CHD biomarker profile of claim 15, comprising polypeptide concentration levels of each of C2C, COMP, PIICP, CTX-II and RANKL, wherein the sample is a serum sample.
